ResearcherDuke UniversityActive in the last 2 years
Julia Button
Matched on OpenAlex author ID A5026098505. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2025: 2 papers · 2026: 1 paper
Papers 3
- Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer. First author DOI 10.1016/j.hpb.2025.11.001↗
- A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. Co-author DOI 10.1007/s00262-025-04146-5↗
- SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Co-author DOI 10.1097/sla.0000000000006966↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elishama N. Kanu · 3 shared papers, 2025–2026 · strength 0.72
- Paper Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer. DOI 10.1016/j.hpb.2025.11.001↗
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Ethan S. Agritelley · 3 shared papers, 2025–2026 · strength 0.72
- Paper Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer. DOI 10.1016/j.hpb.2025.11.001↗
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Daniel P. Nussbaum · 3 shared papers, 2025–2026 · strength 0.72
- Paper Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer. DOI 10.1016/j.hpb.2025.11.001↗
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Peter J. Allen · 2 shared papers, 2025–2026 · strength 0.53
- Michael E. Lidsky · 2 shared papers, 2025 · strength 0.39
- Paper A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. DOI 10.1007/s00262-025-04146-5↗
- Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
- Ryne C. Ramaker · 1 shared paper, 2026 · strength 0.33
- Tao Wang · 1 shared paper, 2025 · strength 0.20
- Erika J. Crosby · 1 shared paper, 2025 · strength 0.20
- Austin M. Eckhoff · 1 shared paper, 2025 · strength 0.20
- Dan German Blazer · 1 shared paper, 2025 · strength 0.20
- Sabino Zani · 1 shared paper, 2025 · strength 0.20
- Erin M. Dickey · 1 shared paper, 2025 · strength 0.19
- David G. Brauer · 1 shared paper, 2025 · strength 0.19
- Caitlin A. Hester · 1 shared paper, 2025 · strength 0.19
- Brian E. Diskin · 1 shared paper, 2025 · strength 0.19
- Emil Lou · 1 shared paper, 2025 · strength 0.19
- Nipun B. Merchant · 1 shared paper, 2025 · strength 0.19
- Brett Logan Ecker · 1 shared paper, 2025 · strength 0.19
- Susanna Varkey Ulahannan · 1 shared paper, 2025 · strength 0.19
- Jashodeep Datta · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.